Estrogen receptor interacts with the downstream mediators of EGFR signaling in NSCLC [39], and that mutation of EGFR correlate with clinical responsiveness to the tyrosine kinase inhibitor [40]. The gene discussed is ESR1; the disease is non-small cell lung carcinoma.